Sarah Kernaghan
Overview
Explore the profile of Sarah Kernaghan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
650
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tovey H, Sipos O, Parker J, Hoadley K, Quist J, Kernaghan S, et al.
Clin Cancer Res
. 2023 Aug;
29(18):3691-3705.
PMID: 37574209
Purpose: The TNT trial (NCT00532727) showed no evidence of carboplatin superiority over docetaxel in metastatic triple-negative breast cancer (mTNBC), but carboplatin benefit was observed in the germline BRCA1/2 mutation subgroup....
2.
Love S, Cafferty F, Snowdon C, Carty K, Savage J, Pallmann P, et al.
Trials
. 2022 Sep;
23(1):757.
PMID: 36068599
Background: Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively...
3.
Snowdon C, Kernaghan S, Moretti L, Turner N, Ring A, Wilkinson K, et al.
Trials
. 2022 May;
23(1):372.
PMID: 35526005
Background: Platform trial designs are used increasingly in cancer clinical research and are considered an efficient model for evaluating multiple compounds within a single disease or disease subtype. However, these...
4.
Kingston B, Cutts R, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, et al.
Nat Commun
. 2021 Jul;
12(1):4479.
PMID: 34272402
No abstract available.
5.
Kingston B, Cutts R, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, et al.
Nat Commun
. 2021 Apr;
12(1):2423.
PMID: 33893289
The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma circulating...
6.
Turner N, Kingston B, Kilburn L, Kernaghan S, Wardley A, Macpherson I, et al.
Lancet Oncol
. 2020 Sep;
21(10):1296-1308.
PMID: 32919527
Background: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the...
7.
Judson I, Morden J, Kilburn L, Leahy M, Benson C, Bhadri V, et al.
Lancet Oncol
. 2019 Jun;
20(7):1023-1034.
PMID: 31160249
Background: Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. The Cediranib...
8.
Tutt A, Tovey H, Chon U Cheang M, Kernaghan S, Kilburn L, Gazinska P, et al.
Nat Med
. 2018 May;
24(5):628-637.
PMID: 29713086
Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs DNA lesions caused...
9.
Fox L, Toms C, Kernaghan S, Snowdon C, Bliss J
Trials
. 2017 Sep;
18(1):440.
PMID: 28950887
Background: Academic clinical trials play a fundamental role in the development of new treatments, the repurposing of existing treatments and in addressing areas of unmet clinical need. With cancer treatments...